Contrasting of Oramed Pharmaceuticals Inc. (ORMP) and Its Peers

We are contrasting Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) and its competitors on their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation. They are Biotechnology companies, competing one another.

Insider and Institutional Ownership

Oramed Pharmaceuticals Inc. has 23.4% of its shares held by institutional investors & an average of 50.88% institutional ownership for its competitors. 5.6% of Oramed Pharmaceuticals Inc. shares are held by company insiders. Comparatively, 8.18% of all Biotechnology companies shares are held by company insiders.

Profitability

Table 1 has Oramed Pharmaceuticals Inc. and its competitors’ return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals Inc. -577.69% -55.90% -31.50%
Industry Average 1,464.25% 88.44% 21.62%

Earnings & Valuation

The following data compares Oramed Pharmaceuticals Inc. and its competitors’ valuation, gross revenue and net income.

Net Income Gross Revenue Price/Earnings Ratio
Oramed Pharmaceuticals Inc. 14.50M 2.51M 0.00
Industry Average 34.08M 2.33M 58.78

Analyst Ratings

Table 3 provides breakdown of recent ratings for Oramed Pharmaceuticals Inc. and its competitors.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Oramed Pharmaceuticals Inc. 0 0 0 0.00
Industry Average 1.17 1.78 2.01 2.68

The potential upside of the rivals is 173.20%.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Oramed Pharmaceuticals Inc. and its competitors.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Oramed Pharmaceuticals Inc. 0% -3.41% -18.73% -45.67% -53.74% -54.67%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Oramed Pharmaceuticals Inc. had bearish trend while Oramed Pharmaceuticals Inc.’s competitors had bullish trend.

Liquidity

The Current Ratio and a Quick Ratio of Oramed Pharmaceuticals Inc. are 6.8 and 6.8. Competitively, Oramed Pharmaceuticals Inc.’s competitors have 7.68 and 7.52 for Current and Quick Ratio. Oramed Pharmaceuticals Inc.’s rivals have better ability to pay short and long-term obligations than Oramed Pharmaceuticals Inc.

Volatility and Risk

A beta of 0.19 shows that Oramed Pharmaceuticals Inc. is 81.00% less volatile than Standard & Poor’s 500. Competitively, Oramed Pharmaceuticals Inc.’s competitors’ beta is 1.70 which is 70.08% more volatile than Standard & Poor’s 500.

Dividends

Oramed Pharmaceuticals Inc. does not pay a dividend.

Summary

On 4 of the 4 factors Oramed Pharmaceuticals Inc.’s rivals beat Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes. The company operates primarily in Israel. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.